{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:54:58Z","timestamp":1790891698739,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ucl.2026.06.007","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:23:28Z","timestamp":1784838208000},"page":"593-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant Therapy in Patients after Cystectomy"],"prefix":"10.1016","volume":"53","author":[{"given":"Saad O.","family":"Atiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan F.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2026.06.007_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.007_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"19","key":"10.1016\/j.ucl.2026.06.007_bib3","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ucl.2026.06.007_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.124","article-title":"LBA2 Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.007_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.007_bib6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0022-5347(17)42861-8","article-title":"Adjuvant chemotherapy of bladder cancer: a preliminary report","volume":"139","author":"Logothetis","year":"1988","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.007_bib7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/annonc\/mdr354","article-title":"Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial","volume":"23","author":"Cognetti","year":"2012","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.ucl.2026.06.007_bib8","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2001.19.20.4005","article-title":"Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC","volume":"19","author":"Millikan","year":"2001","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.ucl.2026.06.007_bib9","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.2010.34.4028","article-title":"Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status","volume":"29","author":"Stadler","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.007_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/UPJ.0000000000000467","article-title":"Neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer: elective and eligibility factors impacting utilization","volume":"11","author":"Patel","year":"2024","journal-title":"Urol Pract"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.007_bib11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.007_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.007_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials","volume":"81","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.007_bib14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.ucl.2026.06.007_bib15","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-Dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.007_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.007_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.007_bib18","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/01.ju.0000118956.96871.18","article-title":"Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic cooperative Oncology Group","volume":"171","author":"Bamias","year":"2004","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.06.007_bib19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00345-022-03948-x","article-title":"Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer","volume":"40","author":"Afferi","year":"2022","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.007_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/BLC-180163","article-title":"The role of adjuvant radiation therapy in locally advanced bladder cancer","volume":"4","author":"Lewis","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ucl.2026.06.007_bib21","series-title":"Bladder adjuvant radiotherapy (BART): clinical outcomes from a phase III multicenter randomized controlled trial","year":"2025"},{"key":"10.1016\/j.ucl.2026.06.007_bib22","author":"Klaassen"},{"issue":"3","key":"10.1016\/j.ucl.2026.06.007_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijrobp.2024.09.040","article-title":"Bladder Adjuvant Radiation Therapy (BART): acute and late toxicity from a phase III multicenter randomized controlled trial","volume":"121","author":"Murthy","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.ucl.2026.06.007_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/JU9.0000000000000046","article-title":"Oncological surveillance after radical cystectomy: a narrative review of the enhanced recovery after surgery cystectomy committee","volume":"1","author":"Kaufmann","year":"2023","journal-title":"JU Open Plus"},{"issue":"4 Pt 1","key":"10.1016\/j.ucl.2026.06.007_bib25","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.juro.2006.06.025","article-title":"Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder","volume":"176","author":"Karakiewicz","year":"2006","journal-title":"J Urol"},{"issue":"3 Pt B","key":"10.1016\/j.ucl.2026.06.007_bib26","first-page":"E30","article-title":"Predictors of cancer-specific mortality after disease recurrence following radical cystectomy","volume":"111","author":"Rink","year":"2013","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.007_bib27","doi-asserted-by":"crossref","first-page":"76.e15","DOI":"10.1016\/j.urolonc.2020.07.011","article-title":"\u201cReal-world\u201d outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma","volume":"39","author":"Drakaki","year":"2021","journal-title":"Urol Oncol: Seminars and Original Investigations"},{"issue":"4","key":"10.1016\/j.ucl.2026.06.007_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.06.007_bib29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.ucl.2026.06.007_bib30","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.007_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.007_bib32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2026.06.007_bib33","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1038\/s41591-025-03802-8","article-title":"Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial","volume":"31","author":"Galsky","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.06.007_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ucl.2026.06.007_bib35","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-Guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ucl.2026.06.007_bib37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8_Supplement_2","key":"10.1016\/j.ucl.2026.06.007_bib38","doi-asserted-by":"crossref","first-page":"CT101","DOI":"10.1158\/1538-7445.AM2025-CT101","article-title":"Abstract CT101: ctdna-guided immunotherapy following cystectomy in patients with urothelial carcinoma: preliminary results from the TOMBOLA trial","volume":"85","author":"Dyrskj\u00f8t","year":"2025","journal-title":"Cancer Res"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:59:20Z","timestamp":1790888360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0094014326000601"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.007","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Therapy in Patients after Cystectomy","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}